The medical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s exhibiting significant efficacy in clinical trials for addressing obesity. Unlike some current weight loss approaches, retatrutide appears to offer a significant substantial loss in body mass and improve metabolic health, particular